22 February 2021

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

22 February 2021 | n=72

  1. Mellor MM, Bast AC, Jones NR, Roberts NW, et al.
    Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis.
    AIDS 2021.

  2. Zou W, Xing J, Wang F, Chen X, et al.
    HIV-1LAI Nef blocks the development of hematopoietic stem/ progenitor cells into T lymphoid cells.
    AIDS 2021.

  3. Rothan C, Yero A, Shi T, Farnos O, et al.
    ART-treated HIV-infected adults with coronary artery disease are characterized by a distinctive regulatory T-cell signature.
    AIDS 2021.

  4. Yang FN, Bronshteyn M, Flowers SA, Dawson M, et al.
    Low CD4 nadir exacerbates the impacts of APOE epsilon4 on functional connectivity and memory in adults with HIV.
    AIDS 2021.

  5. Falade-Nwulia O, Seaberg EC, Snider AE, Rinaldo CR, et al.
    Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.
    AIDS 2021.

  6. Hays AG, Schar M, Barditch-Crovo P, Bagchi S, et al.
    A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV.
    AIDS 2021.

  7. Holt M, Broady TR, Mao L, Chan C, et al.
    Increasing pre-exposure prophylaxis use and 'net prevention coverage' in behavioural surveillance of Australian gay and bisexual men, 2014-19.
    AIDS 2021.

  8. Kimmel SD, Walley AY, Lodi S, Forman LS, et al.
    Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy.
    AIDS 2021.

  9. Hatcher AM, Brittain K, Phillips TK, Zerbe A, et al.
    Longitudinal association between intimate partner violence and viral suppression during pregnancy and postpartum in South African women.
    AIDS 2021.

  10. Nelson M, Winston A, Hill A, Mngqibisa R, et al.
    Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.
    AIDS 2021.

  11. Moodley Y, Tomita A, de Oliveira T, Tanser F, et al.
    HIV viral load and pregnancy loss: Results from a population-based cohort study in rural KwaZulu-Natal, South Africa.
    AIDS 2021.

  12. Shiau S, Brummel SS, Kennedy EM, Hermetz K, et al.
    Longitudinal changes in epigenetic age in youth with perinatally-acquired HIV and youth who are perinatally HIV-exposed uninfected.
    AIDS 2021.

  13. Ekenberg C, Reekie J, Zucco AG, Murray DD, et al.
    The association of HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies.
    AIDS 2021.

  14. Pilkington V, Hughes SL, Pepperrell T, McCann K, et al.
    Tenofovir alafenamide versus tenofovir disoproxil fumarate - an updated meta-analysis of 14,894 patients across 14 trials.
    AIDS 2020.

  15. Banda FM, Powis KM, Sun S, Makhema J, et al.
    Fetal biometry following in utero exposure to dolutegravir- or efavirenz-based antiretroviral therapy.
    AIDS 2020.

  16. Seeley J, Blanc AK.
    Reducing stigma and discrimination: new evidence and its implications.
    AIDS 2020;34 S:S1-S4.

  17. El-Sadr WM.
    What one pandemic can teach us in facing another.
    AIDS 2020;34:1757-1759.

  18. Carr M, Richardson R, Tong W, Bloch M, et al.
    Switch from tenofovir DF to raltegravir is not associated with weight gain over 96 weeks.
    AIDS 2019.

  19. Patel RH, Acharya A, Chand HS, Mohan M, et al.
    HIV and SARS-CoV-2 Co-infection: A Systematic Review of the Literature and Challenges.
    AIDS Res Hum Retroviruses 2021.

  20. da Silva AS, Cavalcanti MDSM, Belmont TFM, Ximenes RAA, et al.
    The 1G/1G + 1G/2G genotypes of MMP1 rs1799750 are associated with higher levels of MMP-1 and are both associated with lipodystrophy in people living with HIV on antiretroviral therapy?
    AIDS Res Hum Retroviruses 2021.

  21. Montano M.
    AIDS Res Hum Retroviruses 2021.

  22. Ciccullo A, Baldin G, Dusina A, Cossu MV, et al.
    Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice.
    AIDS Res Hum Retroviruses 2021.

  23. Weerasuria M, Ko C, Ehm A, O'Bryan J, et al.
    The impact of the COVID-19 pandemic on people living with HIV in Victoria, Australia.
    AIDS Res Hum Retroviruses 2021.

  24. Troyano-Hernaez P, Reinosa R, Burgos MC, Holguin A, et al.
    Update in natural antiretroviral-associated mutations among HIV-2 variants and discrepancies across HIV-2 resistance interpretation tools.
    AIDS Res Hum Retroviruses 2021.

  25. Mdletshe N, Thobakgale C, Malaba TR, Madlala H, et al.
    Low immune activation in early pregnancy is associated with preterm but not small-for-gestational age delivery in HIV infected women initiating antiretroviral therapy in pregnancy: a PIMS case-control study in Cape Town, South Africa.
    Clin Infect Dis 2021.

  26. Dombrowski JC, Wierzbicki MR, Newman LM, Powell JA, et al.
    DoDoxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men who have Sex with Men: A Randomized Controlled Trial.
    Clin Infect Dis 2021.

  27. Yaya I, Boyer V, Ehlan PA, Coulibaly A, et al.
    Heterogeneity in the prevalence of high-risk human papillomavirus infection in HIV-negative and HIV-positive men who have sex with men in West Africa.
    Clin Infect Dis 2021.

  28. Ajibola G, Garcia-Broncano P, Maswabi K, Bennett K, et al.
    Viral Reservoir in Early-Treated HIV-Infected Children and Markers for Sustained Viral Suppression.
    Clin Infect Dis 2021.

  29. Chambers HF, Evans SR, Patel R, Cross HR, et al.
    Antibacterial Resistance Leadership Group 2.0 - Back to Business.
    Clin Infect Dis 2021.

  30. Hassan AS, Hare J, Gounder K, Nazziwa J, et al.
    A Stronger Innate Immune Response During Hyperacute HIV-1 Infection is associated with ACUTE retroviral syndrome.
    Clin Infect Dis 2021.

  31. Little SJ, Chen T, Wang R, Anderson C, et al.
    Effective HIV Molecular Surveillance Requires Identification of Incident Cases of Infection.
    Clin Infect Dis 2021.

  32. Holderman JL, Thomas JC, Schlanger K, Black JM, et al.
    Sustained Transmission of Neisseria gonorrhoeae with High-Level Resistance to Azithromycin, Indianapolis, Indiana 2017-2018.
    Clin Infect Dis 2021.

  33. Town K, Tie Y, Dasgupta S, Kirkcaldy RD, et al.
    Sexually transmitted infection testing among transgender women living with HIV in the United States: Medical Monitoring Project, 2015-2019.
    Clin Infect Dis 2021.

  34. Roussel C, Ndour PA, Kendjo E, Larreche S, et al.
    Intravenous artesunate for the treatment of severe imported malaria: implementation, efficacy and safety in 1391 patients.
    Clin Infect Dis 2021.

  35. Masters MC, Perez J, Wu K, Ellis R, et al.
    Baseline neurocognitive impairment (NCI) is associated with incident frailty but baseline frailty does not predict incident NCI in older persons with HIV.
    Clin Infect Dis 2021.

  36. Sam-Agudu NA, Rabie H, Pipo MT, Byamungu LN, et al.
    The Critical Need for Pooled Data on COVID-19 in African Children: An AFREhealth Call for Action through Multi-Country Research Collaboration.
    Clin Infect Dis 2021.

  37. Bell N, Bracchi M, Dalla Pria A, Nelson M, et al.
    Indirect HIV morbidity and mortality due to COVID-19.
    Clin Infect Dis 2021.

  38. Kuehn BM.
    Global Partnership Aims to Improve Infant HIV Care.
    JAMA 2021;325:612.

  39. Nijhawan AE, Mathews WC, Raifman J, Fleming J, et al.
    Hospitalization rates among persons with HIV who gained Medicaid or private insurance after the Affordable Care Act in 2014.
    J Acquir Immune Defic Syndr 2021.

  40. Mgodi NM, Takuva S, Edupuganti S, Karuna S, et al.
    A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa: baseline findings.
    J Acquir Immune Defic Syndr 2021.

  41. Palefsky JM, Poongulali S, Lensing S, Lee J, et al.
    AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent vaccine in Indian Women Living with HIV.
    J Acquir Immune Defic Syndr 2021.

  42. Price JT, Vwalika B, Edwards JK, Cole SR, et al.
    Maternal HIV infection and spontaneous versus provider-initiated preterm birth in an urban Zambian cohort.
    J Acquir Immune Defic Syndr 2021.

  43. Huang SH, Huang WC, Lin SW, Chuang YC, et al.
    Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV.
    J Acquir Immune Defic Syndr 2021.

  44. Pelchen-Matthews A, Borges AH, Reekie J, Rasmussen LD, et al.
    Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with Human Immunodeficiency Virus in a European Cohort.
    J Acquir Immune Defic Syndr 2021.

  45. Edupuganti S, Mgodi N, Karuna ST, Andrew P, et al.
    Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
    J Acquir Immune Defic Syndr 2021.

  46. Cachay ER, Torriani FJ, Hill L, Rajagopal A, et al.
    HCV knowledge and Recent Diagnosis Affect HCV Treatment Willingness in Persons Living with HIV.
    J Acquir Immune Defic Syndr 2021.

  47. Vera JH, Eftychiou N, Schuerer M, Rullmann M, et al.
    J Acquir Immune Defic Syndr 2021.

  48. Nowak RG, Liska TA, Bentzen SM, Kim E, et al.
    Herpes Simplex Virus Type-2 shedding and genital ulcers during early HIV in Zimbabwean women.
    J Acquir Immune Defic Syndr 2021.

  49. Truong HM, Fatch R, McFarland W, Raymond HF, et al.
    HIV Prevention Responsibility Beliefs Among Men Who Have Sex with Men in the PrEP Era.
    J Acquir Immune Defic Syndr 2021.

  50. van Wyk J, Ait-Khaled M, Santos J, Scholten S, et al.
    Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    J Acquir Immune Defic Syndr 2021.

  51. Kohn JN, Loop MS, Kim-Chang JJ, Garvie PA, et al.
    Trajectories of depressive symptoms, neurocognitive function and viral suppression with antiretroviral therapy among youth with HIV over 36 months.
    J Acquir Immune Defic Syndr 2021.

  52. Wang L, Tan DHS, Mishra S.
    Evidence of Nonrandom Mixing by Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men Partnerships in Melbourne, 2016 to 2018.
    J Acquir Immune Defic Syndr 2020;84:e22-e23.

  53. Safer JD.
    Research gaps in medical treatment of transgender/nonbinary people.
    J Clin Invest 2021;131.

  54. Perez-Diez A, Wong CS, Liu X, Mystakelis H, et al.
    Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia.
    J Clin Invest 2020;130:5326-5337.

  55. Vujkovic-Cvijin I, Sortino O, Verheij E, Wit FW, et al.
    The complement pathway is activated in people with HIV and is associated with non-AIDS comorbidities.
    J Infect Dis 2021.

  56. Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al.
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis 2021.

  57. Banhart S, Selb R, Oehlmann S, Bender J, et al.
    The mosaic mtr locus as major genetic determinant of azithromycin resistance of Neisseria gonorrhoeae, Germany, 2018.
    J Infect Dis 2021.

  58. Li C, Mori L, Valente ST.
    The Block-and-Lock Strategy for Human Immunodeficiency Virus Cure: Lessons Learned from Didehydro-Cortistatin A.
    J Infect Dis 2021;223:46-53.

  59. Siliciano JD, Siliciano RF.
    Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
    J Infect Dis 2021;223:13-21.

  60. Li JZ, Gandhi RT.
    The Search for an HIV Cure: Where Do We Go From Here?
    J Infect Dis 2021;223:1-3.

  61. Li Y, Mohammadi A, Li JZ.
    Challenges and Promise of Human Immunodeficiency Virus Remission.
    J Infect Dis 2021;223:4-12.

  62. Rossignol E, Alter G, Julg B.
    Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.
    J Infect Dis 2021;223:22-31.

  63. Kaseke C, Tano-Menka R, Senjobe F, Gaiha GD, et al.
    The Emerging Role for CTL Epitope Specificity in HIV Cure Efforts.
    J Infect Dis 2021;223:32-37.

  64. Zhou Y, Maldini CR, Jadlowsky J, Riley JL, et al.
    Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.
    J Infect Dis 2021;223:38-45.

  65. Olusola BA, Olaleye DO, Odaibo GN.
    New Infections and HIV-1 Subtypes Among Febrile Persons and Blood Donors in Oyo State, Nigeria.
    J Med Virol 2021.

  66. Zhao Z, Fagerlund R, Baur AS, Saksela K, et al.
    HIV-1 Nef-induced secretion of the proinflammatory protease TACE into extracellularvesicles is mediated by Raf-1, and can be suppressed by clinical protein kinase inhibitors.
    J Virol 2021.

  67. Pierini V, Gallucci L, Sturzel CM, Kirchhoff F, et al.
    SERINC5 can Enhance Pro-inflammatory Cytokine Production by Primary Human Myeloid Cells in Response to Challenge with HIV-1 Particles.
    J Virol 2021.

  68. Reyes Diaz LM, Lastre Gonzalez MSJB, Cuello M, Sierra-Gonzalez VG, et al.
    VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
    Pediatr Infect Dis J 2021.

  69. Angerstein AO, Stoneham CA, Ramirez PW, Guatelli JC, et al.
    Corrigendum to "Sensitivity to monoclonal antibody 447-52D and an open env trimer conformation correlate poorly with inhibition of HIV-1 infectivity by SERINC5" [Virology 2020 548, 73-81].
    Virology 2021.

  70. Jaguva Vasudevan AA, Balakrishnan K, Franken A, Krikoni A, et al.
    Murine leukemia virus resists producer cell APOBEC3A by its Glycosylated Gag but not target cell APOBEC3A.
    Virology 2021;557:1-14.

  71. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, et al.
    Covid-19 deaths in Africa: prospective systematic postmortem surveillance study.
    BMJ 2021;372:n334.

  72. Arnold C.
    Covid-19: How the lessons of HIV can help end the pandemic.
    BMJ 2021;372:n216.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

01 March 2021

22 February 2021

15 February 2021

08 February 2021

01 February 2021

22 February 2021

Multidisciplinary Journal Club

  1. Page K, Melia MT, Veenhuis RT, Winter M, et al.
    Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection.
    N Engl J Med. 2021;384:541-549.

  2. Wahl A, Gralinski LE, Johnson CE, Yao W, et al.
    SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
    Nature. 2021 Feb 9. pii: 10.1038/s41586-021-03312.

  3. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, et al.
    Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.050991.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016